Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Allon Therapeutics Inc NPCUF

Allon Therapeutics, Inc. is a Canada-based Company, which develops treatments for neurodegenerative diseases. The Company is engaged in pre-clinical and clinical development of proprietary neuroprotective compounds which may be applied for the potential treatment of Alzheimer's Disease, Parkinson's Disease, senile dementia, glaucoma, traumatic head injury, neuronal damage due to stroke and... see more

GREY:NPCUF - Post Discussion

Allon Therapeutics Inc > Market sluggish
View:
Post by CBalardo on Jul 25, 2017 12:31am

Market sluggish

I love this stock. I'm going to triple my money in 2 1/2 years or less I hope. Cheers share holders
Comment by Vimon66 on Jul 28, 2017 10:33pm
There margins are so low that there is no substantial value creation even on the long run. With time if you get stuck onboard you'll come to hope for one thing only and that is a buyout offer. Let's pray that the board doesn't get too at ease cause if the past is any indications of what the future holds, we surely shouldn't expect riches any time soon. Good luck to you anyway!
Comment by poubelle1 on Jul 29, 2017 9:51am
The thesis for buying this stock is that we take advantage of a strong investment cycle in infrasture spending in the US and growth through acquisition. An expansion in margins is a bonus, and possible since the base now is low.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities